multiple sclerosis

Most Impressive Drug Launch: Roche's Ocrevus
BioPharma Dive
Mon, 12/4/17 - 11:41 am
Roche
Ocrevus
drug launches
MS
multiple sclerosis
Alkermes shares rise 6% on Biogen multiple sclerosis drug partnership
Marketwatch
Mon, 11/27/17 - 09:10 am
Alkermes
Biogen
MS
multiple sclerosis
ALKS 8700
Sanofi bolsters its position on multiple sclerosis with a $765M BTK licensing deal
Endpoints
Thu, 11/9/17 - 12:02 pm
Sanofi
multiple sclerosis
MS
Principia Biopharma
How Aubagio became the most switched-to oral MS drug
Medical Marketing and Media
Tue, 10/31/17 - 10:02 am
Aubagio
MS
multiple sclerosis
Sanofi
Late-stage ozanimod data brings Celgene closer to filing
BioPharma Dive
Mon, 10/30/17 - 02:56 pm
ozanimod
Celgene
MS
multiple sclerosis
Bloodied Celgene posts promising ozanimod PhIII MS data, but is it really a $6 billion drug?
Endpoints
Mon, 10/30/17 - 09:56 am
Celgene
ozaminod
MS
multiple sclerosis
[forum discussion]Should rank reports be eliminated?
Cafepharma Message Boards
Thu, 10/12/17 - 09:26 am
drug reps
MS
multiple sclerosis
Genentech
FDA offers surprise OK for Mylan’s Copaxone knockoffs, slamming Teva
Endpoints
Wed, 10/4/17 - 12:17 pm
FDA
Mylan Labs
Copaxone
Teva Pharmaceutical
MS
multiple sclerosis
After a long, painful revamp, Merck KGaA scores key OK for once-defunct MS drug cladribine
Endpoints
Fri, 08/25/17 - 09:57 am
Merck KGaA
MS
multiple sclerosis
cladribine
Drug blocked by European regulators improves quality of life for MS patients
Drug Delivery Business News
Fri, 08/18/17 - 12:09 pm
Europe
MS
multiple sclerosis
cladribine
Lawmakers dig into 'skyrocketing' MS costs with probe into 7 drugmakers
Fierce Pharma
Thu, 08/17/17 - 11:48 pm
multiple sclerosis
MS
drug pricing
Bayer
Biogen
Merck KGaA
Novartis
Sanofi
Teva Pharmaceutical
Roche
Biotechs Find Strength In Numbers In Treating Multiple Sclerosis
Investors Business Daily
Fri, 07/21/17 - 10:25 am
MS
multiple sclerosis
Roche
Celgene
Novartis
Biogen
ozanimod
Gilenya
Ocrevus
Extavia
How Biogen Inc. Makes Most of Its Money
Motley Fool
Thu, 07/13/17 - 05:43 pm
Biogen
Tecfidera
Tysabri
MS
multiple sclerosis
EMA Restricts Use of Biogen MS Drug
RAPS.org
Sun, 07/9/17 - 11:39 am
Europe
EMA
Biogen
MS
multiple sclerosis
Zinbryta
Biogen aims to block Tecfidera generics with flurry of lawsuits
Bizjournals.com
Tue, 07/4/17 - 11:22 pm
Biogen
Tecfidera
generics
MS
multiple sclerosis
Novartis
Sandoz
Mylan Labs
2 Pharma Buyout Targets That May Surprise You
Motley Fool
Tue, 06/27/17 - 09:46 am
Biogen
Bristol-Myers Squibb
M&A
MS
multiple sclerosis
immuno-oncology
Roche's Ocrevus racks up more positive MS data in relapsing and primary progressive forms
Fierce Pharma
Sat, 06/24/17 - 09:14 am
Roche
Ocrevus
MS
multiple sclerosis
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Sat, 06/24/17 - 09:11 am
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda
Mylan's Copaxone copy could face another hold-up with FDA info request
Fierce Pharma
Fri, 06/16/17 - 09:56 pm
Mylan
Copaxone
FDA
generics
Teva Pharmaceutical
MS
multiple sclerosis
Roche looks into PML report for Ocrevus patient
BioPharma Dive
Thu, 05/25/17 - 11:25 am
Roche
PML
Ocrevus
Genentech
MS
multiple sclerosis

Pages